StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA by Year

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA: -9.9% in FY2025, down 13.3 pts from a year earlier. That is the lowest of the 9 years on record here.

Latest, FY2025
-9.9%
Period ended Dec 28, 2025
Change on a year earlier
-13.3 pts
3.4% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| WW | 3,810 | 4,222 | (9.8) | (9.9) | 0.1”

Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedINVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
FY2025Dec 28, 2025-9.9%-13.3 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
FY2024Dec 29, 20243.4%+3.4 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
FY2023Dec 31, 20230.0%-6.9 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
FY2022Jan 1, 20236.9%-2.1 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
FY2021Jan 2, 20229.0%-0.6 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
FY2020Jan 3, 20219.6%-6.2 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
FY2019Dec 29, 201915.8%+2.7 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
FY2018Dec 30, 201813.1%-2.6 ptsForm 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗
FY2017Dec 31, 201715.7%–Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗

Breakdown

What makes up INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA

Cite this data

StockData. (2026). Johnson & Johnson INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (%), annual FY2017–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-invega-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.